Boston, MA, United States of America

Gabriel Musso

This inventor holds 1 USPTO granted patent. Top assignee: The Brigham and Women's Hospital, Inc.. Active years: 2026.


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gabriel Musso: Innovator in Drug Discovery

Introduction

Gabriel Musso is a prominent inventor based in Boston, MA, known for his contributions to the field of drug discovery and therapeutics. His innovative work focuses on methods for drug screening and compositions that inhibit cell proliferation and survival. With a single patent to his name, Musso is making significant strides in the medical research community.

Latest Patents

Musso's patent, titled "Methods for drug screening and compositions useful for the inhibition of cell proliferation and/or cell survival," relates to drug discovery and therapeutics. The patent outlines systems and methods to predict drug function, classify or prioritize drugs based on their predicted function, and test both known and novel compounds for efficacy in a vertebrate system. This work is particularly relevant for developing cancer therapeutics, as it identifies novel mechanisms of action for various compounds.

Career Highlights

Gabriel Musso is affiliated with The Brigham and Women's Hospital, Inc., where he conducts his research. His work is instrumental in advancing the understanding of drug interactions and therapeutic applications, particularly in oncology. Musso's dedication to improving drug discovery processes has positioned him as a valuable asset in the medical research field.

Collaborations

Due to space constraints, the collaborations section has been omitted.

Conclusion

Gabriel Musso's innovative contributions to drug discovery and therapeutics highlight his commitment to advancing medical research. His work has the potential to significantly impact cancer treatment and improve patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…